Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
AQEMIA logo — Scale drug discovery with quantum-inspired physics and gener...

AQEMIA

Scale drug discovery with quantum-inspired physics and generative AI

Founded 2019 France France 87 employees Total: $115.18M AI, Biotechnology +3

General Information

Company Name AQEMIA
Founded Year 2019
Location France France
Founders / Decision Makers
Team member
Employees 87
Industries AI, Biotechnology, Life Sciences +2
Business Model B2B, SaaS, Platform
Revenue Model Licensing, Project Based, Service Fee
Hiring 14 roles posted in the month to 2 Nov 2026
Offices as of Oct 2026
Paris, France London, United Kingdom
Social

BounceWatch is an independent company data service, not affiliated with AQEMIA. To contact AQEMIA, visit aqemia.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does AQEMIA compare?

A PDF of AQEMIA and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting AQEMIA soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

Recorded by Bounce Watch from public sources. Every entry below carries the date we observed it, and when we have not looked recently the page says so rather than leaving silence to imply nothing happened.

Actively Hiring Oct 31, 2026

Hiring for 14 positions in the last 30 days.

New Partnership Oct 13, 2026

AQEMIA's CEO, Maximilien Levesque, collaborated with GROUPE MACSF for an episode of their podcast, "Ça ira mieux demain".

Get alerts when AQEMIA shows new signals

About AQEMIA

AQEMIA, founded in 2019, is a cutting-edge company at the intersection of AI and biotechnology, focusing on drug discovery through the use of quantum-inspired physics and generative AI. The company specializes in creating novel medicines to address significant diseases, particularly in the oncology space, and is known for seeking solutions beyond the capabilities of traditional R&D.

Headquartered in France, with additional operations in London, AQEMIA is part of the French Tech 120 program, highlighting its potential for global impact. The company's innovative platform has already led to several discovery successes and collaborations with top pharmaceutical firms, moving promising candidates toward in vivo optimization.

In its most recent financial milestone, AQEMIA secured a $7.40M grant investment led by France 2030 on April 1, 2025. This boost underscores investor confidence in AQEMIA's pioneering approach in the life sciences sector and its ongoing growth trajectory.

Business keywords: Drug Discovery, Quantum-inspired Physics, Generative AI, Pharmaceutical R&D, TechBio, PharmaTech, Computational Chemistry, Oncology, AI Drug Discovery, Drug Design, Physics-based Technology, Atomic Scale Physics, Biopharma, Immuno-Oncology

Services & Products

AI-driven drug discovery
Development of next-generation medicines

Target Customers

Pharmaceutical companies Biotech researchers Healthcare providers

Funding Rounds & Investors (7)

View All
Funding Stage Amount Investors Lead Investors Date
Grant $7.40M 1
France 2030
01 Apr 2025
Early VC €35.98M 5
Cathay Innovation Bpifrance Elaia Partners
Cathay Innovation, Bpifrance +3
01 Dec 2024
Series A €30.00M 4
Bpifrance Elaia Partners Wendel Group
Bpifrance, Elaia Partners +2
01 Jan 2024
Series A €30.00M 3
Bpifrance Elaia Partners
Bpifrance, Elaia Partners +1
01 Oct 2022
Series A $10.20M 2
Elaia Partners
Elaia Partners, Eurazeo
01 Jan 2021
Support Program €1.60M 1
Elaia Partners
Elaia Partners
01 Oct 2019
Spinout Undisclosed 3
CNRS Innovation
CNRS Innovation, French National Centre for Scientific Research - CNRS +1
01 Jul 2019

Latest News

View All
Elaia closes €134M fund DTS3 to back Europe’s next generation of breakthrough startups — Tech
Elaia closes €134M fund DTS3 to back Europe’s next generation of breakthrough startups
Tech Mar 12, 2026
Elaia closes third DeepTech Seed fund at €134 million as “European DeepTech is reaching escape veloc... — Eu-startups
Elaia closes third DeepTech Seed fund at €134 million as “European DeepTech is reaching escape velocity”
Eu-startups Mar 12, 2026
Biotech Aqemia secures €7M grant for drug discovery using deep physics — Tech
Biotech Aqemia secures €7M grant for drug discovery using deep physics
Tech Apr 01, 2025
Cambridge startup analyses ‘multi-omics’ data to discover new heart drugs — Thenextweb
Cambridge startup analyses ‘multi-omics’ data to discover new heart drugs
Thenextweb Sep 10, 2024
10 French startups to watch in 2024 — Tech
10 French startups to watch in 2024
Tech Mar 26, 2024
As European dynamism gathers momentum, Elaia and partners double down with new deep tech fund — Techcrunch
As European dynamism gathers momentum, Elaia and partners double down with new deep tech fund
Techcrunch Mar 14, 2024

AQEMIA Alternatives & Competitors

View All Alternatives
AQEMIA vs
Recursion
Recursion United States

Decoding Biology to Radically Improve Lives

IPO
770 employees
AI, Biotechnology
Compare AQEMIA vs Recursion
AQEMIA vs
Algorithmiq
Algorithmiq Italy

Building the algorithmic layer that makes quantum computing useful.

Series B
52 employees
Biotechnology, Life Sciences
Compare AQEMIA vs Algorithmiq
AQEMIA vs
Menten AI
Menten AI United States

Unlocking the potential of peptides macrocycles to create tomorrow's life-changing medicines with Ge...

Seed
19 employees
AI, Biotechnology
Also compare with: AQEMIA vs Evozyne Evozyne View all alternatives

FAQ About AQEMIA

Scale drug discovery with quantum-inspired physics and generative AI
AQEMIA was founded in 2019.
AQEMIA is headquartered in France. As of Oct 2026, it also has offices in Paris, France and London, United Kingdom.
AQEMIA operates in AI, Biotechnology, Life Sciences, Pharmaceutical and Machine Learning. Its work centres on Drug Discovery, Quantum-inspired Physics, Generative AI and Pharmaceutical R&D. Its customers include Pharmaceutical companies, Biotech researchers and Healthcare providers.
AQEMIA has a B2B, SaaS and Platform business model. Its revenue comes from Licensing, Project Based and Service Fee.
AQEMIA has approximately 87 employees.
AQEMIA has completed 7 funding rounds, raising a total of $115.18M.
AQEMIA offers: AI-driven drug discovery, Development of next-generation medicines.
Top alternatives and competitors to AQEMIA include Recursion, Algorithmiq, Menten AI, Genesis Molecular AI, XtalPi Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
AQEMIA and Recursion are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for AQEMIA, https://bouncewatch.com/company/aqemia, updated 16 October 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes